William Feldman: Looking at payer-negotiated prices on oncology drugs at pediatric 340B hospitals

William Feldman, Assistant Professor at Harvard Medical School and Ethics Co-Chair at Brigham and Women’s Hospital, shared a post by Program On Regulation, Therapeutics, And Law, on X, adding:

”We have a new paper out looking at payer-negotiated prices on oncology drugs at pediatric 340B hospitals. Led by Program On Regulation, Therapeutics, And Law‘s Ian Liu and Aviva Wang.”

Quoting Program On Regulation, Therapeutics, And Law’s post:

”NEW: Analysis led by Ian Liu examines oncology drug mark-ups at 340B pediatric hospitals. These hospitals can extract steep payments for these drugs from commercial insurers, with median payments ranging from 102-630% of the average sales price.”

Source: William Feldman/X and Program On Regulation, Therapeutics, And Law/X